# A Double-Blinded, Randomized, Vehicle-Controlled Study of the Efficacy of Moisturizer Containing Licochalcone A, Decanediol, L-Carnitine, and Salicylic Acid for Prevention of Acne Relapse in Asian Population

Authors: Kanokvalai Kulthanan; Suphattra Trakanwittayarak; Papapit Tuchinda; Leena Chularojanamontri; Pichaya Limphoka; Supenya Varothai
Journal: BioMed Research International
 (2020)

---

## Abstract

Many topical agents are available for treating the acute phase of acne; however, few agents have been proven beneficial during the maintenance phase.Objective. To evaluate the efficacy and safety of moisturizer containing licochalcone A, 1,2-decanediol, L-carnitine, and salicylic acid during the maintenance phase of mild to moderate acne in Thai patients. Methods. One hundred and ten patients with mild to moderate acne vulgaris were initially treated with a fixed combination of adapalene 0.1%/benzoyl peroxide 2.5% gel once daily for 8 weeks. Fifty patients who achieved at least 50% reduction in lesion counts or at least a 2-grade improvement in the Investigator’s Global Assessment (IGA) grade from baseline were enrolled in the maintenance phase, which was an investigator-masked, left-right comparison, randomized, controlled, intraindividual study. Moisturizers with and without the active study ingredients were applied twice a day to each side of the face, respectively, for 12 weeks. Assessments included acne lesion counts, acne severity by IGA scoring, skin bioengineering measurements, and skin tolerability as assessed by both patient and physician. Results. The treatment group had a significant reduction in the mean counts of noninflammatory, inflammatory, and total lesions compared to the vehicle group at week 12 and also between baseline and week 12. There was no significant difference in the mean scores for skin dryness, stinging/burning, or pruritus at any time point between groups. Conclusions. Moisturizer containing licochalcone A, 1,2-decanediol, L-carnitine, and salicylic acid reduced acne lesions and prevented the development of new lesions during the maintenance phase. This trial is registered with ClinicalTrials.gov registration no. NCT04002024.


---

## Body

## 1. Introduction

Acne vulgaris is a common dermatological condition with a prevalence up to 85% among adolescents [1]. The four main mechanisms that lead to acne are abnormal keratinization, excessive sebum production, proliferation of Cutibacterium acne (C. acnes), and inflammation [2]. The current treatments for acne are based on acne severity, which is categorized as mild, moderate, or severe [3]. Patients with mild disease are treated with topical regimens, including retinoids, benzyl peroxide, and/or antibiotics, and systemic treatments are added for patients with moderate to severe acne [1, 4]. Since acne is considered to be a persistent and relapsing inflammatory disease, a long-term maintenance therapy should be considered [5]. Antibiotic monotherapy, either topical or systemic therapy, was discouraged for maintenance therapy due to the development of C. acnes antibiotic resistance [4]. Topical retinoids are recommended as a mainstay treatment during the maintenance phase [6]. However, there are various cutaneous side effects, such as erythema, dryness, itching, stinging, and photosensitivity. Among topical retinoids, adapalene was reported to cause less skin irritation [7, 8]. As such, the side effects of topical retinoids may lead to a poor patient compliance and unsuccessful treatment [9].Topical dermocosmetics with active ingredients that target the pathogenesis of acne have become a treatment of interest for maintenance therapy [10]. The roles of antiacne dermocosmetics as an adjunctive therapy may include prevention and maintenance, delivering synergistic effect, and management of side effects of antiacne medication [11]. The ideal dermocosmetics for acne should be noncomedogenic, hypoallergenic, nonirritating, and compatible with acne treatment [12]. Moisturizer containing active ingredients, such as licochalcone, 1,2-decanediol, L-carnitine, and salicylic acid, for the treatment of acne was reported to have beneficial effects when combined with standard treatments [13–16]. Licochalcone A has a highly effective anti-inflammatory effect [17], decanediol has antibacterial efficacy against C. acnes [18], and L-carnitine can reduce sebum production [19]. Salicylic acid at low concentration has mild comedolytic and corneolytic efficacy [20, 21].The aim of this study was to evaluate the efficacy and safety of moisturizer containing licochalcone A, decanediol, L-carnitine, and 1% salicylic acid compared with placebo during the maintenance phase of mild to moderate acne vulgaris in Thai patients, which might represent Asian population.


## 2. Materials and Methods

### 2.1. Study Design

This 8-week open-label and 12-week, double-blind, randomized, vehicle-controlled study was conducted at the Department of Dermatology of the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, during June 2019 to January 2020. This study was registered at the ClinicalTrials.gov website (registration no.NCT04002024), and it was approved by the Siriraj Institutional Review Board (SIRB) (COA no. Si 079/2019). All subjects provided written informed consent prior to entering the study.


### 2.2. Study Population

Male and female participants aged more than 18 years who were diagnosed as acne vulgaris by dermatologists were enrolled. Acne vulgaris was defined by polymorphic lesions of comedones, erythematous papules, pustules, and nodules on a seborrheic area. Patients who had acne on both cheeks with mild to moderate severity consistent with an Investigator’s Global Assessment (IGA) [22] score of 2 or 3 were recruited. The exclusion criteria were patients with the following: (i) other types of acne, (ii) other active skin diseases on the face for the previous 2 weeks, (iii) receiving systemic treatment for acne within 4 weeks prior to the start of this study, (iv) history of allergic contact dermatitis to any of the ingredients in the test product, (v) history of adverse reactions to doxycycline, and/or (vi) pregnant or breastfeeding women. Eligible female subjects must have used any reliable contraceptive method besides oral contraceptive pills for at least 1 month prior to the start of this study and must have agreed to do the same for at least 6 months after the completion of the study.


### 2.3. Sample Size Calculation

In a study by Leyden et al. [23], 189 patients with moderate to moderately-severe acne vulgaris were enrolled to investigate the maintenance effect of 3 regimens (topical tazarotene, oral minocycline hydrochloride, or both) for treating patients with acne vulgaris. The improvement in patients receiving tazarotene and in patients receiving minocycline hydrochloride were adopted to calculate our sample size. In that study, the percentage difference in the mean inflammatory lesion count from baseline was −54.0±25.1 and −66.0±29.4 in the tazarotene and minocycline hydrochloride groups, respectively. Assuming a significance level of 0.05 and 80% power, 50 patients were required to detect a 1-point difference in the mean inflammatory lesion count, and a 2.5-point difference in the standard deviation (SD) between groups during the maintenance phase.From studies by Gold et al. [24] and Poulin et al. [25] 53% of patients receiving doxycycline 100 mg and adapalene 0.1%/benzoyl peroxide 2.5% gel had at least 50% improvement after 12 weeks of treatment. Accordingly, if 50 patients were required for the maintenance phase, at least 100 patients would be required for the induction phase. To compensate for a dropout rate of 10% for any reason, a total of 110 patients were enrolled in the induction phase of this study.


### 2.4. Study Treatments

This study was divided into 2 phases—the induction phase and the maintenance phase. All patients were allowed to use only lipstick and their previously and regularly used face puffs after enrollment in the study. Other skin care products and other topical or systemic acne medications were prohibited throughout the study period. A specific cleanser (pH 5.5 mild cleanser without perfumes, hypoallergenic, and hypocomedogenic) was provided for all patients throughout the study period. Study moisturizer and placebo were provided for patients who met the criteria for inclusion in the maintenance phase.During the induction phase (an 8-week open-label study), 110 patients with mild to moderate acne vulgaris, based on IGA scoring, were treated with a fixed combination of adapalene 0.1%/benzoyl peroxide 2.5% gel once daily for 8 weeks. In cases with moderate acne severity, 1-2 capsules of oral doxycycline per day were added for 1-2 months and then stopped prior to the maintenance phase. Patients who had at least 50% reduction in the number of acne vulgaris or at least a 2-grade improvement in IGA grading from baseline were enrolled in the maintenance phase.For the maintenance phase (a 12-week double-blind, randomized, vehicle-controlled study), 50 patients were randomized into 5 blocks with 10 block sizes to apply moisturizer containing active ingredients (licochalcone A, decanediol, L-carnitine, and 1% salicylic acid) and placebo, which was identical to the moisturizer vehicle without the mentioned active ingredients. Patients were asked to regularly apply the moisturizer containing active ingredients and placebo (one on each side of the face) twice daily (one fingertip unit per each application) for 12 weeks.The same investigator evaluated the skin condition of each patient during every visit. Patients were followed up every 4 weeks for 12 weeks. A flowchart of the study protocol is shown in Figure1. Outcomes were assessed according to acne lesion counts, acne severity according to IGA scoring, skin bioengineering measurements, and skin tolerability as assessed by both patients and physicians. All data were analyzed at the end of the study.Figure 1
Flowchart of the study protocol. IGA: Investigator’s Global Assessment.


### 2.5. Outcome and Methods of Evaluation

(i)
Efficacy Evaluation. Efficacy rates were evaluated based on the count of noninflammatory acne lesions, inflammatory acne lesions, and total acne lesions and the IGA score at every visit during the maintenance phase. The severity of acne was graded according to IGA score [22], as follows: 0=clear (no inflammatory or noninflammatory lesion), 1=almost clear (rare noninflammatory lesions with no more than one small inflammatory lesion), 2=mild (some noninflammatory lesions with no more than a few inflammatory lesions, but no nodular lesions), 3=moderate (many noninflammatory lesions and may have some inflammatory lesions, but no more than one small nodular lesion), and 4=severe (up to many noninflammatory and inflammatory lesions, but no more than a few nodular lesions). The maintenance rate was defined as the percentage of patients who maintained at least 50% improvement in the total lesion count between baseline of the maintenance phase and week 12 [26].(ii)
Skin Bioengineering Evaluation. The following skin bioengineering measurements [27] were assessed: (i) water content of the stratum corneum by Corneometer® CM 825 (Courage-Khazaka, Cologne, Germany), (ii) transepidermal water loss (TEWL) by Tewameter® TM 300 (Courage-Khazaka, Cologne, Germany), and (iii) sebum amount by Sebumeter® SM 815 (Courage-Khazaka, Cologne, Germany) at baseline and weeks 4, 8, and 12. Before each set of measurements, participants were required to equilibrate in a closed standard environment with a constant temperature (20±2°C) and humidity (45-55% relative humidity). All measurements were taken by the same investigator.(iii)
Skin Tolerability Evaluation. Skin tolerability was evaluated by 5 parameters, including erythema, dryness, scaling, stinging/burning, and pruritus. All 5 parameters were assessed by the patient, and erythema, dryness, and scaling were evaluated by physicians. Results were recorded using a 4-point scale (0=none, 1=mild, 2=moderate, and 3=severe) on each side of the face at weeks 4, 8, and 12. Overall patient tolerance assessment was rated on a scale ranging from 0 to 3 (0=poor, 1=fair, 2=good, and 3=excellent) at weeks 4, 8, and 12.(iv)
Skin Radiance Evaluation. Skin radiance was measured on each half-face at the beginning and end of the study by patients using a visual analog scale (VAS). The minimum score is 0 (no radiance at all), and the maximum score is 10 (most radiant) [28].(v)
Satisfaction Evaluation. Patient satisfaction was assessed at weeks 4, 8, and 12 using a 4-point scale (0=notatall, 1=mild, 2=moderate, and 3=verysatisfied) [29]. Overall patient satisfaction was assessed using a VAS at week 12. Similarly, physician satisfaction was evaluated at weeks 4, 8, and 12 using a 4-point scale (0=poor, 1=fair, 2=good, and 3=excellent), and overall physician satisfaction was assessed using a VAS at week 12.(vi)
Photographic Evaluation. Standard facial photographs were taken to evaluate the clinical presentation of acne vulgaris. Digital ultraviolet (UV) fluorescence photography was performed using VISIA Complexion Analysis (software version 6.4.2, Canfield Scientific, Parsippany, NJ, USA). UV fluorescence photography demonstrates porphyrins that are produced by C. acnes and that become lodged in pores. Porphyrins demonstrate orange-red fluorescence under UVA light [30].


### 2.6. Statistical Analysis

PASW Statistics version 18 (SPSS, Inc., Chicago, IL, USA) was used for data analysis. All statistical tests were two-sided, and statistical significance was declared at ap value less than 0.05. A paired t-test was used to analyze changes in lesion counts, differences in skin bioengineering measurements, skin tolerability assessment, overall patient tolerance, skin radiance VAS score, patient/physician satisfaction, and patient/physician satisfaction VAS scores. The general linear model with repeated measure was used to analyze data within groups. McNemar’s test was used to analyze the maintenance rate. Data are presented as the mean±SD or number and percentage.


## 2.1. Study Design

This 8-week open-label and 12-week, double-blind, randomized, vehicle-controlled study was conducted at the Department of Dermatology of the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, during June 2019 to January 2020. This study was registered at the ClinicalTrials.gov website (registration no.NCT04002024), and it was approved by the Siriraj Institutional Review Board (SIRB) (COA no. Si 079/2019). All subjects provided written informed consent prior to entering the study.


## 2.2. Study Population

Male and female participants aged more than 18 years who were diagnosed as acne vulgaris by dermatologists were enrolled. Acne vulgaris was defined by polymorphic lesions of comedones, erythematous papules, pustules, and nodules on a seborrheic area. Patients who had acne on both cheeks with mild to moderate severity consistent with an Investigator’s Global Assessment (IGA) [22] score of 2 or 3 were recruited. The exclusion criteria were patients with the following: (i) other types of acne, (ii) other active skin diseases on the face for the previous 2 weeks, (iii) receiving systemic treatment for acne within 4 weeks prior to the start of this study, (iv) history of allergic contact dermatitis to any of the ingredients in the test product, (v) history of adverse reactions to doxycycline, and/or (vi) pregnant or breastfeeding women. Eligible female subjects must have used any reliable contraceptive method besides oral contraceptive pills for at least 1 month prior to the start of this study and must have agreed to do the same for at least 6 months after the completion of the study.


## 2.3. Sample Size Calculation

In a study by Leyden et al. [23], 189 patients with moderate to moderately-severe acne vulgaris were enrolled to investigate the maintenance effect of 3 regimens (topical tazarotene, oral minocycline hydrochloride, or both) for treating patients with acne vulgaris. The improvement in patients receiving tazarotene and in patients receiving minocycline hydrochloride were adopted to calculate our sample size. In that study, the percentage difference in the mean inflammatory lesion count from baseline was −54.0±25.1 and −66.0±29.4 in the tazarotene and minocycline hydrochloride groups, respectively. Assuming a significance level of 0.05 and 80% power, 50 patients were required to detect a 1-point difference in the mean inflammatory lesion count, and a 2.5-point difference in the standard deviation (SD) between groups during the maintenance phase.From studies by Gold et al. [24] and Poulin et al. [25] 53% of patients receiving doxycycline 100 mg and adapalene 0.1%/benzoyl peroxide 2.5% gel had at least 50% improvement after 12 weeks of treatment. Accordingly, if 50 patients were required for the maintenance phase, at least 100 patients would be required for the induction phase. To compensate for a dropout rate of 10% for any reason, a total of 110 patients were enrolled in the induction phase of this study.


## 2.4. Study Treatments

This study was divided into 2 phases—the induction phase and the maintenance phase. All patients were allowed to use only lipstick and their previously and regularly used face puffs after enrollment in the study. Other skin care products and other topical or systemic acne medications were prohibited throughout the study period. A specific cleanser (pH 5.5 mild cleanser without perfumes, hypoallergenic, and hypocomedogenic) was provided for all patients throughout the study period. Study moisturizer and placebo were provided for patients who met the criteria for inclusion in the maintenance phase.During the induction phase (an 8-week open-label study), 110 patients with mild to moderate acne vulgaris, based on IGA scoring, were treated with a fixed combination of adapalene 0.1%/benzoyl peroxide 2.5% gel once daily for 8 weeks. In cases with moderate acne severity, 1-2 capsules of oral doxycycline per day were added for 1-2 months and then stopped prior to the maintenance phase. Patients who had at least 50% reduction in the number of acne vulgaris or at least a 2-grade improvement in IGA grading from baseline were enrolled in the maintenance phase.For the maintenance phase (a 12-week double-blind, randomized, vehicle-controlled study), 50 patients were randomized into 5 blocks with 10 block sizes to apply moisturizer containing active ingredients (licochalcone A, decanediol, L-carnitine, and 1% salicylic acid) and placebo, which was identical to the moisturizer vehicle without the mentioned active ingredients. Patients were asked to regularly apply the moisturizer containing active ingredients and placebo (one on each side of the face) twice daily (one fingertip unit per each application) for 12 weeks.The same investigator evaluated the skin condition of each patient during every visit. Patients were followed up every 4 weeks for 12 weeks. A flowchart of the study protocol is shown in Figure1. Outcomes were assessed according to acne lesion counts, acne severity according to IGA scoring, skin bioengineering measurements, and skin tolerability as assessed by both patients and physicians. All data were analyzed at the end of the study.Figure 1
Flowchart of the study protocol. IGA: Investigator’s Global Assessment.


## 2.5. Outcome and Methods of Evaluation

(i)
Efficacy Evaluation. Efficacy rates were evaluated based on the count of noninflammatory acne lesions, inflammatory acne lesions, and total acne lesions and the IGA score at every visit during the maintenance phase. The severity of acne was graded according to IGA score [22], as follows: 0=clear (no inflammatory or noninflammatory lesion), 1=almost clear (rare noninflammatory lesions with no more than one small inflammatory lesion), 2=mild (some noninflammatory lesions with no more than a few inflammatory lesions, but no nodular lesions), 3=moderate (many noninflammatory lesions and may have some inflammatory lesions, but no more than one small nodular lesion), and 4=severe (up to many noninflammatory and inflammatory lesions, but no more than a few nodular lesions). The maintenance rate was defined as the percentage of patients who maintained at least 50% improvement in the total lesion count between baseline of the maintenance phase and week 12 [26].(ii)
Skin Bioengineering Evaluation. The following skin bioengineering measurements [27] were assessed: (i) water content of the stratum corneum by Corneometer® CM 825 (Courage-Khazaka, Cologne, Germany), (ii) transepidermal water loss (TEWL) by Tewameter® TM 300 (Courage-Khazaka, Cologne, Germany), and (iii) sebum amount by Sebumeter® SM 815 (Courage-Khazaka, Cologne, Germany) at baseline and weeks 4, 8, and 12. Before each set of measurements, participants were required to equilibrate in a closed standard environment with a constant temperature (20±2°C) and humidity (45-55% relative humidity). All measurements were taken by the same investigator.(iii)
Skin Tolerability Evaluation. Skin tolerability was evaluated by 5 parameters, including erythema, dryness, scaling, stinging/burning, and pruritus. All 5 parameters were assessed by the patient, and erythema, dryness, and scaling were evaluated by physicians. Results were recorded using a 4-point scale (0=none, 1=mild, 2=moderate, and 3=severe) on each side of the face at weeks 4, 8, and 12. Overall patient tolerance assessment was rated on a scale ranging from 0 to 3 (0=poor, 1=fair, 2=good, and 3=excellent) at weeks 4, 8, and 12.(iv)
Skin Radiance Evaluation. Skin radiance was measured on each half-face at the beginning and end of the study by patients using a visual analog scale (VAS). The minimum score is 0 (no radiance at all), and the maximum score is 10 (most radiant) [28].(v)
Satisfaction Evaluation. Patient satisfaction was assessed at weeks 4, 8, and 12 using a 4-point scale (0=notatall, 1=mild, 2=moderate, and 3=verysatisfied) [29]. Overall patient satisfaction was assessed using a VAS at week 12. Similarly, physician satisfaction was evaluated at weeks 4, 8, and 12 using a 4-point scale (0=poor, 1=fair, 2=good, and 3=excellent), and overall physician satisfaction was assessed using a VAS at week 12.(vi)
Photographic Evaluation. Standard facial photographs were taken to evaluate the clinical presentation of acne vulgaris. Digital ultraviolet (UV) fluorescence photography was performed using VISIA Complexion Analysis (software version 6.4.2, Canfield Scientific, Parsippany, NJ, USA). UV fluorescence photography demonstrates porphyrins that are produced by C. acnes and that become lodged in pores. Porphyrins demonstrate orange-red fluorescence under UVA light [30].


## 2.6. Statistical Analysis

PASW Statistics version 18 (SPSS, Inc., Chicago, IL, USA) was used for data analysis. All statistical tests were two-sided, and statistical significance was declared at ap value less than 0.05. A paired t-test was used to analyze changes in lesion counts, differences in skin bioengineering measurements, skin tolerability assessment, overall patient tolerance, skin radiance VAS score, patient/physician satisfaction, and patient/physician satisfaction VAS scores. The general linear model with repeated measure was used to analyze data within groups. McNemar’s test was used to analyze the maintenance rate. Data are presented as the mean±SD or number and percentage.


## 3. Results

### 3.1. Demographic and Clinical Characteristics

One hundred and ten patents were enrolled in the induction phase, and 50 patients (11 males, 39 females; mean age 28.2 years) who had at least 50% reduction in the number of acne lesions or at least a 2-grade improvement in IGA grading from baseline were included in the maintenance phase. None of the patients withdrew during the maintenance therapy. The demographic and clinical characteristics of these 50 patients are shown in Table1. There were no significant differences in these characteristics or in skin bioengineering data between the treatment and placebo sides of the face.Table 1
Baseline characteristics compared between the treatment side and placebo side (split-face study) during the maintenance phase (N=50).
VariablesMean±SD or N (%)p valueTreatment sidePlacebo sideClinical characteristicsAcne lesion countsNoninflammatory8.4±5.88.7±5.50.684Inflammatory2.1±1.91.7±1.30.060Total10.5±6.510.3±5.90.766IGA scale for acne vulgarisGrade 1 (almost clear)19 (38%)26 (52%)0.147Grade 2 (mild severity)24 (48%)18 (36%)Grade 3 (moderate severity)7 (14%)6 (12%)Skin bioengineering measurementsCorneometer (corneometer unit)70.4±13.069.6±12.90.164Tewameter (g/h/m2)13.2±6.813.9±8.50.463Sebumeter (μg/cm2)41.2±24.440.4±25.90.603Ap value < 0.05 indicates statistical significance. SD: standard deviation; IGA: Investigator’s Global Assessment.


### 3.2. Efficacy Evaluation

After 12 weeks of maintenance therapy, the treatment group had a significant reduction in lesion count compared to the placebo group for each lesion type (noninflammatory, inflammatory, and total lesions), as shown in Figure2. The mean values of noninflammatory count and total lesion count were significantly reduced at week 8 and week 12 compared to the placebo group (Figures 2(a) and 2(c), respectively), while the mean inflammatory lesion count was significantly reduced at week 12 (Figure 2(b)).Figure 2
Comparison of (a) the mean noninflammatory lesion count, (b) inflammatory lesion count, (c) total lesion count, and (d) Investigator’s Global Assessment of acne severity between the treatment side and placebo side at baseline and at weeks 4, 8, and 12.ΔSignificant intergroup difference (p<0.05). ∗Significant intragroup difference (p<0.05).
(a)(b)(c)(d)The treatment group had a significant reduction in mean noninflammatory, inflammatory, and total lesions from baseline to week 12 (Figures2(a)–2(c), respectively). The placebo group also had a significant reduction in inflammatory lesion count from baseline to week 8 (Figure 2(b)) and in total lesion count from baseline to week 4 and from baseline to week 8 (Figure 2(c)). However, at the end of the study, lesion counts for all acne types rose substantially to nearly the same number of lesions counted at baseline in the placebo group (Figures 2(a)–2(c)). There was no significant reduction in the noninflammatory lesion count in the placebo group at any time point during the study period (Figure 2(a)).Most patients in the treatment group shifted from grade 2 or 3 to grade 0 or 1, which is defined as clear or almost clear as assessed by IGA scoring (Figure2(d)). The treatment group had a significantly higher mean total lesion count maintenance rate from baseline to week 12 (56%) than the placebo group (36%) (p=0.021).


### 3.3. Skin Bioengineering Evaluation

Skin bioengineering evaluation data at each follow-up visit are shown in Table2. Water content of the stratum corneum as assessed by Corneometer tended to increase from baseline to all time points in the treatment group. TEWL scores in both groups tended to decrease from baseline. However, none of the immediately aforementioned increases or decreases achieved statistical significance. In contrast, there was a significant reduction in skin sebum content in the treatment group compared to the placebo group at week 12.Table 2
Skin bioengineering evaluation compared between the treatment side and placebo side (split-face study) during the maintenance phase (N=50).
VariablesMean±SDp valueTreatment sidePlacebo sideSkin hydration (corneometer unit)Baseline70.4±13.069.6±12.90.164Week 471.8±10.969.4±13.30.140Week 872.9±11.070.7±11.80.174Week 1271.2±12.169.3±13.20.237Transepidermal water loss (g/h/m2)Baseline13.2±6.813.9±8.50.463Week 411.7±8.69.9±4.40.166Week 810.2±5.710.9±5.00.197Week 1210.1±5.110.6±5.40.415Sebumeter (μg/cm2)Baseline41.2±24.440.4±25.90.603Week 439.9±26.143.3±22.70.147Week 837.7±25.040.8±28.40.111Week 1235.3±26.439.7±27.90.029∗∗A p value < 0.05 indicates statistical significance. SD: standard deviation.


### 3.4. Skin Tolerability Evaluation

The scores for the skin tolerability, including erythema, dryness, scaling, stinging/burning, and pruritus, are shown in Table3. Patients evaluated erythema, dryness, scaling, sting/burning, and pruritus, whereas physicians evaluated erythema, dryness, and scaling. There were no significant differences in the mean scores for dryness, stinging/burning, or pruritus at any time point between treatment and placebo groups. Moreover, the treatment group had significantly less scaling than the placebo group at week 8. A more significant reduction in the mean erythema and scaling scores as assessed by the physicians were observed in the treatment group compared to the placebo group at week 12.Table 3
Tolerability assessment compared between the treatment side and placebo side (split-face study) during the maintenance phase (N=50).
VariablesMean±SDp valueTreatment sidePlacebo sidePatient evaluationErythema (score=0-3)Baseline1.6±0.81.6±0.80.554Week 41.1±0.81.2±0.80.659Week 80.9±0.81.0±0.80.278Week 120.9±0.91.0±0.80.351Dryness (score=0-3)Baseline1.4±1.11.5±0.90.212Week 41.0±0.91.0±0.90.497Week 80.8±0.80.9±0.90.133Week 120.8±0.90.9±0.90.444Scaling (score=0-3)Baseline1.1±0.91.08±0.91.000Week 40.4±0.60.4±0.71.000Week 80.4±0.60.7±0.80.001∗Week 120.5±0.70.6±0.80.622Stinging/burning (score=0-3)Baseline0.7±0.70.8±0.70.766Week 40.4±0.80.3±0.60.204Week 80.5±0.70.6±0.90.135Week 120.2±0.50.3±0.60.485Pruritus (score=0-3)Baseline0.7±0.80.7±0.71.000Week 40.3±0.60.7±0.50.371Week 80.4±0.70.4±0.61.000Week 120.3±0.60.3±0.51.000Physician evaluationErythema (score=0-3)Baseline1.8±0.61.9±0.70.302Week 41.3±0.61.4±0.60.110Week 81.2±0.61.3±0.60.182Week 121.0±0.61.2±0.40.044∗Dryness (score=0-3)Baseline1.0±0.61.0±0.60.569Week 40.7±0.50.7±0.51.000Week 80.6±0.50.6±0.60.322Week 120.6±0.60.6±0.70.420Scaling (score=0-3)Baseline0.6±0.70.6±0.70.322Week 40.2±0.50.2±0.41.000Week 80.3±0.50.3±0.80.420Week 120.3±0.50.5±0.70.005∗∗A p value < 0.05 indicates statistical significance. Scoring: 0=none, 1=mild, 2=moderate, and 3=severe. N: number; SD: standard deviation.There was a significantly higher mean overall patient tolerance score in the treatment group than the placebo group at week 12 (p=0.011). Most patients in the treatment group shifted their rating of overall patient tolerance from good at baseline to excellent at week 12. No serious or severe adverse events were reported.


### 3.5. Skin Radiance Evaluation

Skin radiance as assessed by a patient-rated VAS score increased from baseline in both groups. However, the treatment group had a significantly higher mean score than the placebo group at week 12 (p=0.014).


### 3.6. Rating of Patient and Physician Satisfaction

The treatment group had a higher mean patient satisfaction score than the placebo group at all time points. Most patients in the treatment group shifted their rating of satisfaction from moderate at baseline to very satisfied at week 12. In addition, the treatment group had a significantly higher mean VAS score for patient satisfaction than the placebo group at week 12 (p=0.009).The treatment group had a significantly higher mean physician satisfaction score than the placebo group at week 12 (p<0.001). Most patients in the treatment group shifted the rating by physician assessment from good at the baseline towards good and excellent at week 12. Moreover, the treatment group had a significantly higher mean VAS score for physician satisfaction than the placebo group at week 12 (p<0.001).


### 3.7. Photographic Evaluation

The clinical response of one patient at baseline, week 4, week 8, and week 12 is shown in Figure3. The treatment side showed better clinical response than the placebo side. Digital UV fluorescence photography showed a marked reduction in porphyrins excreting from C. acnes in the treatment group compared to the placebo group at week 12 (Figure 4).Figure 3
Representative photographs of an acne vulgaris patient compared between the treatment side and the placebo side of the face at baseline and at weeks 4, 8, and 12. The treatment side had better clinical response than the placebo side.Figure 4
Digital ultraviolet fluorescence photography comparingCutibacterium acnes (C. acnes) between the treatment side and the placebo side of the face at baseline and at weeks 4, 8, and 12. The treatment side had a much lower amount of C. acnes than the placebo side.


## 3.1. Demographic and Clinical Characteristics

One hundred and ten patents were enrolled in the induction phase, and 50 patients (11 males, 39 females; mean age 28.2 years) who had at least 50% reduction in the number of acne lesions or at least a 2-grade improvement in IGA grading from baseline were included in the maintenance phase. None of the patients withdrew during the maintenance therapy. The demographic and clinical characteristics of these 50 patients are shown in Table1. There were no significant differences in these characteristics or in skin bioengineering data between the treatment and placebo sides of the face.Table 1
Baseline characteristics compared between the treatment side and placebo side (split-face study) during the maintenance phase (N=50).
VariablesMean±SD or N (%)p valueTreatment sidePlacebo sideClinical characteristicsAcne lesion countsNoninflammatory8.4±5.88.7±5.50.684Inflammatory2.1±1.91.7±1.30.060Total10.5±6.510.3±5.90.766IGA scale for acne vulgarisGrade 1 (almost clear)19 (38%)26 (52%)0.147Grade 2 (mild severity)24 (48%)18 (36%)Grade 3 (moderate severity)7 (14%)6 (12%)Skin bioengineering measurementsCorneometer (corneometer unit)70.4±13.069.6±12.90.164Tewameter (g/h/m2)13.2±6.813.9±8.50.463Sebumeter (μg/cm2)41.2±24.440.4±25.90.603Ap value < 0.05 indicates statistical significance. SD: standard deviation; IGA: Investigator’s Global Assessment.


## 3.2. Efficacy Evaluation

After 12 weeks of maintenance therapy, the treatment group had a significant reduction in lesion count compared to the placebo group for each lesion type (noninflammatory, inflammatory, and total lesions), as shown in Figure2. The mean values of noninflammatory count and total lesion count were significantly reduced at week 8 and week 12 compared to the placebo group (Figures 2(a) and 2(c), respectively), while the mean inflammatory lesion count was significantly reduced at week 12 (Figure 2(b)).Figure 2
Comparison of (a) the mean noninflammatory lesion count, (b) inflammatory lesion count, (c) total lesion count, and (d) Investigator’s Global Assessment of acne severity between the treatment side and placebo side at baseline and at weeks 4, 8, and 12.ΔSignificant intergroup difference (p<0.05). ∗Significant intragroup difference (p<0.05).
(a)(b)(c)(d)The treatment group had a significant reduction in mean noninflammatory, inflammatory, and total lesions from baseline to week 12 (Figures2(a)–2(c), respectively). The placebo group also had a significant reduction in inflammatory lesion count from baseline to week 8 (Figure 2(b)) and in total lesion count from baseline to week 4 and from baseline to week 8 (Figure 2(c)). However, at the end of the study, lesion counts for all acne types rose substantially to nearly the same number of lesions counted at baseline in the placebo group (Figures 2(a)–2(c)). There was no significant reduction in the noninflammatory lesion count in the placebo group at any time point during the study period (Figure 2(a)).Most patients in the treatment group shifted from grade 2 or 3 to grade 0 or 1, which is defined as clear or almost clear as assessed by IGA scoring (Figure2(d)). The treatment group had a significantly higher mean total lesion count maintenance rate from baseline to week 12 (56%) than the placebo group (36%) (p=0.021).


## 3.3. Skin Bioengineering Evaluation

Skin bioengineering evaluation data at each follow-up visit are shown in Table2. Water content of the stratum corneum as assessed by Corneometer tended to increase from baseline to all time points in the treatment group. TEWL scores in both groups tended to decrease from baseline. However, none of the immediately aforementioned increases or decreases achieved statistical significance. In contrast, there was a significant reduction in skin sebum content in the treatment group compared to the placebo group at week 12.Table 2
Skin bioengineering evaluation compared between the treatment side and placebo side (split-face study) during the maintenance phase (N=50).
VariablesMean±SDp valueTreatment sidePlacebo sideSkin hydration (corneometer unit)Baseline70.4±13.069.6±12.90.164Week 471.8±10.969.4±13.30.140Week 872.9±11.070.7±11.80.174Week 1271.2±12.169.3±13.20.237Transepidermal water loss (g/h/m2)Baseline13.2±6.813.9±8.50.463Week 411.7±8.69.9±4.40.166Week 810.2±5.710.9±5.00.197Week 1210.1±5.110.6±5.40.415Sebumeter (μg/cm2)Baseline41.2±24.440.4±25.90.603Week 439.9±26.143.3±22.70.147Week 837.7±25.040.8±28.40.111Week 1235.3±26.439.7±27.90.029∗∗A p value < 0.05 indicates statistical significance. SD: standard deviation.


## 3.4. Skin Tolerability Evaluation

The scores for the skin tolerability, including erythema, dryness, scaling, stinging/burning, and pruritus, are shown in Table3. Patients evaluated erythema, dryness, scaling, sting/burning, and pruritus, whereas physicians evaluated erythema, dryness, and scaling. There were no significant differences in the mean scores for dryness, stinging/burning, or pruritus at any time point between treatment and placebo groups. Moreover, the treatment group had significantly less scaling than the placebo group at week 8. A more significant reduction in the mean erythema and scaling scores as assessed by the physicians were observed in the treatment group compared to the placebo group at week 12.Table 3
Tolerability assessment compared between the treatment side and placebo side (split-face study) during the maintenance phase (N=50).
VariablesMean±SDp valueTreatment sidePlacebo sidePatient evaluationErythema (score=0-3)Baseline1.6±0.81.6±0.80.554Week 41.1±0.81.2±0.80.659Week 80.9±0.81.0±0.80.278Week 120.9±0.91.0±0.80.351Dryness (score=0-3)Baseline1.4±1.11.5±0.90.212Week 41.0±0.91.0±0.90.497Week 80.8±0.80.9±0.90.133Week 120.8±0.90.9±0.90.444Scaling (score=0-3)Baseline1.1±0.91.08±0.91.000Week 40.4±0.60.4±0.71.000Week 80.4±0.60.7±0.80.001∗Week 120.5±0.70.6±0.80.622Stinging/burning (score=0-3)Baseline0.7±0.70.8±0.70.766Week 40.4±0.80.3±0.60.204Week 80.5±0.70.6±0.90.135Week 120.2±0.50.3±0.60.485Pruritus (score=0-3)Baseline0.7±0.80.7±0.71.000Week 40.3±0.60.7±0.50.371Week 80.4±0.70.4±0.61.000Week 120.3±0.60.3±0.51.000Physician evaluationErythema (score=0-3)Baseline1.8±0.61.9±0.70.302Week 41.3±0.61.4±0.60.110Week 81.2±0.61.3±0.60.182Week 121.0±0.61.2±0.40.044∗Dryness (score=0-3)Baseline1.0±0.61.0±0.60.569Week 40.7±0.50.7±0.51.000Week 80.6±0.50.6±0.60.322Week 120.6±0.60.6±0.70.420Scaling (score=0-3)Baseline0.6±0.70.6±0.70.322Week 40.2±0.50.2±0.41.000Week 80.3±0.50.3±0.80.420Week 120.3±0.50.5±0.70.005∗∗A p value < 0.05 indicates statistical significance. Scoring: 0=none, 1=mild, 2=moderate, and 3=severe. N: number; SD: standard deviation.There was a significantly higher mean overall patient tolerance score in the treatment group than the placebo group at week 12 (p=0.011). Most patients in the treatment group shifted their rating of overall patient tolerance from good at baseline to excellent at week 12. No serious or severe adverse events were reported.


## 3.5. Skin Radiance Evaluation

Skin radiance as assessed by a patient-rated VAS score increased from baseline in both groups. However, the treatment group had a significantly higher mean score than the placebo group at week 12 (p=0.014).


## 3.6. Rating of Patient and Physician Satisfaction

The treatment group had a higher mean patient satisfaction score than the placebo group at all time points. Most patients in the treatment group shifted their rating of satisfaction from moderate at baseline to very satisfied at week 12. In addition, the treatment group had a significantly higher mean VAS score for patient satisfaction than the placebo group at week 12 (p=0.009).The treatment group had a significantly higher mean physician satisfaction score than the placebo group at week 12 (p<0.001). Most patients in the treatment group shifted the rating by physician assessment from good at the baseline towards good and excellent at week 12. Moreover, the treatment group had a significantly higher mean VAS score for physician satisfaction than the placebo group at week 12 (p<0.001).


## 3.7. Photographic Evaluation

The clinical response of one patient at baseline, week 4, week 8, and week 12 is shown in Figure3. The treatment side showed better clinical response than the placebo side. Digital UV fluorescence photography showed a marked reduction in porphyrins excreting from C. acnes in the treatment group compared to the placebo group at week 12 (Figure 4).Figure 3
Representative photographs of an acne vulgaris patient compared between the treatment side and the placebo side of the face at baseline and at weeks 4, 8, and 12. The treatment side had better clinical response than the placebo side.Figure 4
Digital ultraviolet fluorescence photography comparingCutibacterium acnes (C. acnes) between the treatment side and the placebo side of the face at baseline and at weeks 4, 8, and 12. The treatment side had a much lower amount of C. acnes than the placebo side.


## 4. Discussion

Maintenance therapy after successful induction treatment might be beneficial for preventing lesions from relapsing by suppressing the development of microcomedones and by targetingC. acnes colonization [3]. Dermocosmetics are being increasingly used in the long-term treatment of acne vulgaris [11]. Angelova-Fischer et al. [13] showed that moisturizer containing licochalcone A, L-carnitine, and 1,2-decanediol efficiently improved mild to moderate severe acne compared to a vehicle cream. Chularojanamontri et al. [14] reported that a moisturizer containing these ingredients could encourage patient adherence and improve unfavorable adverse effects, such as irritation. Dall’Oglio et al. [15] suggested that the daily licochalcone A moisturizer with salicylic acid/L-carnitine as fluid or with hydroxy complex 10% as cream was used as an adjunctive treatment for mild acne. Recently, Wanitphakdeedecha et al. [16] reported that a moisturizer containing the active ingredients of licochalcone A, L-carnitine, 1,2-decanediol, and salicylic acid, which are the same ingredients as those used in our study moisturizer, provided good synergistic effect when combined with photodynamic therapy to treat acne.The present study demonstrated that moisturizer containing licochalcone A, L-carnitine, 1,2-decanediol, and salicylic acid could maintain the clinical response produced by 8 weeks of induction phase treatment for acne. The treatment group had a significant reduction in noninflammatory, inflammatory, and total lesions at the end of the study and a significantly higher maintenance rate for total lesions compared to the placebo group.Table4 shows data from previously published randomized controlled studies of the maintenance phase of acne therapy compared to the present study. Our result demonstrated that the treatment group had a significantly higher maintenance rate for mean total lesions (56%) compared to the placebo group (36%). Among 5 previous studies of maintenance phase of acne therapy [8, 23, 25, 26, 31], Thielitz et al. [8] recruited patients with mild to moderate acne whereas the others enrolled patients with moderate to severe acne. The maintenance rate in the treatment group in our study in patients with mild to moderate acne using dermocosmetic as monotherapy was slightly lower than the rate using adapalene in the study of Thielitz et al. [8]Table 4
Literature review of randomized controlled studies that investigated maintenance therapy for acne compared with that of the present study.
Thiboutot et al. [34], 2005; Thiboutot et al. [31], 2006Leyden et al. [23], 2006Thielitz et al. [8], 2007Alirezai et al. [26], 2007Gold et al. [24], 2010; Poulin et al. [25], 2011The present study, 2020Induction phaseNumber of patients46718954242459110Acne severitySevereModerately severe to severeMild to moderateModerate to moderately severeSevereMild to moderateTreatmentAdapalenegel0.1%+doxycycline100mg versus doxycycline100mg+vehicleTazarotenegel0.1%+minocycline100mgAdapalene0.1%+BPO2.5%gelLymecycline300mg+adapalene gel 0.1% versus lymecycline300mg+vehicleDoxycycline100mg+adapalene-BPO 2.5% gel versus doxycycline100mg+vehicleFixed combination of adapalene 0.1% andBPO2.5%gel±doxycycline100-200 mg(moderate cases)Duration12 weeks12 weeks8 weeks12 weeks12 weeks8 weeksMaintenance phaseDefinition of respondersAt least 50% improvement from baselineAt least 75% improvement from baselineSubjects who successfully completed the combination phase entered the 12-week maintenance phaseAt least moderate improvement from baselineAt least 50% global improvement after a treatment phaseAt least 50% reduction in lesion counts or at least 2-grade improvements according to IGA score from baselineNumber of patients2531104913624350 (split-face study)TreatmentAdapalene gel 0.1% versus vehicleTazarotenegel0.1%+placebocapsules versus vehiclegel+minocyclinecapsules versus tazarotenegel0.1%+minocycline capsulesAdapalene daily versus adapalene in alternation with its vehicle versus vehicleAdapalene gel 0.1% versus vehicleAdapalene-BPO 2.5% gel versus vehicleMoisturizer with and without the active ingredients containing of licochalcone A, 1,2-decanediol, L-carnitine, and salicylic acidDuration16 weeks12 weeks12 weeks12 weeks24 weeks12 weeksMaintenance rate∗Adapalene maintenance therapy resulted in significantly larger maintenance rate of total lesions compared with vehicle (75%vs. 54%; p<0.01)At week 12, more than 80% of patients in each group had maintained a 50% improvement in total lesions from baseline with no significanceAdapalene daily maintenance therapy resulted in higher maintenance rate of total lesions (68%vs. 59% vs. 41%), however no statistical significanceAdapalene maintenance therapy resulted in significantly larger maintenance rate of total lesions compared with vehicle (84.7%vs. 63.5%; p=0.0049)At week 24, adapalene-BPO gel resulted in significantly higher maintenance rate for total lesions (78%vs. 45.8%; p<0.001)The treatment group had a significantly higher maintenance rate for mean total lesion count between baseline and week 12 (56%) compared to the vehicle group (36%) (p=0.021)∗Maintenance rate was defined as the percentage of patients who maintained at least 50% improvement in the total lesion count when entering the maintenance phase from baseline to the end of the study. BPO: benzoyl peroxide; IGA: Investigator’s Global Assessment.Various active ingredients may lead to favorable acne control outcomes. Licochalcone A is an extract ofGlycyrrhiza inflata, which has anti-inflammatory and antimicrobial properties. An in vivo study demonstrated its anti-irritative effects, including a significant decrease in erythema in shave-related and UV-induced erythema procedures [17]. 1,2-Decanediol was shown to reduce the growth of C. acnes, and it inhibited C. acnes biofilm formation [18]. Increased sebum production is one of the main pathogenic factors that contribute to the development of acne lesions [32]. L-Carnitine was recently demonstrated to decrease sebum secretion via stimulation of β-oxidation and reduced intracellular lipid content in human sebocytes [19]. Salicylic acid is a beta-hydroxy acid that has keratolytic, comedolytic, and anti-inflammatory properties, and it was shown to have favorable effect on both noninflammatory and inflammatory acne lesions [20, 21].A corneometer was used to evaluate skin surface hydration [33]. In our study, the treatment group had slight improvement in skin hydration compared to baseline, but the placebo group did not. However, there was no statistically significant difference. TEWL is the amount of water that passively evaporates through the skin to the external environment due to water vapor pressure gradient on both sides of the skin barrier. The measurement of TEWL or skin surface vapor loss is a good indicator of the integrity of skin barrier function or the skin’s ability to retain moisture. TEWL in both groups in this study tended to decrease from baseline. This might be explained by the properties of the vehicle that was used in both the treatment and placebo moisturizers. However, sebumeter measurement showed sebum production in patients in the treatment group to be significantly lower than the sebum production in the placebo group at week 12. This result supports that the treatment solution can reduce sebum production due to the property of L-carnitine. Satisfaction assessment by both patients and physicians showed significantly greater satisfaction with the moisturizer containing the active ingredients than the placebo moisturizer at the end of the study.


### 4.1. Study Limitations

This study included only patients with mild to moderate acne severity. Further studies should evaluate the efficacy of the studied active ingredients as maintenance therapy in patients with more severe acne, in a larger population, and for a longer period of time.


## 4.1. Study Limitations

This study included only patients with mild to moderate acne severity. Further studies should evaluate the efficacy of the studied active ingredients as maintenance therapy in patients with more severe acne, in a larger population, and for a longer period of time.


## 5. Conclusions

This study demonstrated the efficacy and safety of moisturizer containing licochalcone A, decanediol, L-carnitine, and salicylic acid as maintenance therapy in Thai patients with mild to moderate severity acne, which might represent the Asian population. This moisturizer could reduce the development of new acne lesions, as well as prevent acne relapse.



---

*Source: 2857812-2020-10-23.xml*